SEI Investments Distribution Co. (1 Freedom Valley Drive, Oaks, PA, 19456) is the distributor for the Global X Funds.
Check the background of SIDCO and Global X's Registered Representatives on FINRA's BrokerCheck.
Get the latest news and updates from our team.
Genomics & Biotechnology ETF
HEAL seeks to invest in companies transforming healthcare through cutting-edge technology, targeting four sub-themes: AI-enabled drug discovery, smart medical devices, tech-enabled consumer healthcare, and healthcare analytics and software solutions.
EBIZ seeks to invest in companies positioned to benefit from the increased adoption of E-commerce as a distribution model, including those operating E-commerce platforms, providing E-commerce software and services, and selling goods and services online.
AGNG seeks to provide exposure to companies positioned to serve the world's rapidly expanding senior population, spanning pharmaceuticals, biotechnology, and health care services that extend lifespans and enhance quality of life in advanced age.
GNOM can complement broad health care or biotech allocations by offering more targeted exposure to the innovation behind potential future phases of health care growth.
The strategy can provide greater participation in an emerging growth opprtunity while seeking to offer exposure to sources of that growth beyond traditional biotech, including the tools and technologies supporting continued advances across the industry.
Manufacturing genomic medicines is cumbersome, but new techniques using donated cells are more scalable and could slash production costs by 95%, potentially facilitating broader adoption.1
Recent regulatory approvals have helped genomic medicines gain momentum. Sales of genomic medicines are forecast to increase at a 37% compound annual growth rate from 2024-2030.2
GNOM provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.
1International Society for Cell and Gene Therapy, Feb 2019
2Evaluate Pharma, n.d., Technology Overviews of: Cell Therapy, Gene Therapy, Gene-Modified Cell Therapy, and Genome Editing, all accessed 17 Sep 2026.
Investing in Pharma: How to Spot Leading Drug Candidates
Novel therapeutic agents can differentiate themselves via a host of factors, which may also impact potential revenue opportunities. Charting Disruption.
Arelis Agosto
Investing in Pharma: The Drug Lifecycle
In the Pipeline: Top Drug Candidates for FDA Approval in 2024
The financial statements include the Fund's disclosures required by Items 7 through 11 of Form N-CSR, which includes the financial statements, financial highlights, and other important information when applicable.
The financial statements include the Fund's disclosures required by Items 7 through 11 of Form N-CSR, which includes the financial statements, financial highlights, and other important information when applicable.
Drug development is key to pharmaceutical industry success, and it’s crucial for investors to understand a drug’s lifecycle to navigate this dynamic sector.
Arelis Agosto
Several promising drugs may be approved in 2024, which could provide Eli Lilly, Moderna, and Bristol Myers Squibb with potentially attractive growth catalysts.
Arelis Agosto
As of Nov 9, 2026
Net Assets (%) | Ticker | Name | SEDOL | Market Price ($) | Shares Held | Market Value ($) |
|---|---|---|---|---|---|---|
| 13.80% | MRNA | MODERNA INC | BGSXTS3 | $269.00 | 55,981 | $15,058,889 |
| 5.93% | TWST | TWIST BIOSCIENCE CORP | BGKG6G7 | $135.34 | 47,793 | $6,468,305 |
| 5.48% | TXG |
Holdings are subject to change. "Cash" denotes U.S. dollars.
Nov 9, 2026
30-Day SEC Yield
-0.31%
Distribution Frequency
Semi-Annually
Record Date | Payable Date | Amount | |
|---|---|---|---|
| Dec 30, 2026 | Dec 30, 2026 | Jan 7, 2027 | - |
| Jun 29, 2026 | Jun 29, 2026 | Jul 7, 2026 | $0.06 |
Metric | 1 Year | 3 Year | 5 Year | Since Inception |
|---|---|---|---|---|
Fund NAV | +55.02% | +25.79% | -3.79% | +1.93% |
Market Price | +55.33% | +25.91% | -3.76% | +2.20% |
Index | +55.55% | +26.44% | -3.34% | +2.42% |
As of Nov 9, 2026
As of Nov 9, 2026
As of Nov 9, 2026
What is Premium/Discount Chart?
How can the Fund trade at a premium/discount to its NAV?
What causes these time discrepancies?
As of Nov 9, 2026
As of Oct 31, 2026
| Industry | Weight (%) |
|---|---|
Pharmaceuticals, Biotechnology & Life Sciences | 87.02% |
Health Care Equipment & Services | 10.00% |
Capital Goods | 2.98% |
| Industry | Weight (%) |
|---|---|
Pharmaceuticals, Biotechnology & Life Sciences | 87.02% |
Health Care Equipment & Services | 10.00% |
Capital Goods | 2.98% |
| Country |
|---|
Source: AltaVista Research, LLC
All Sector, Industry, Commodity and Geographic breakdowns, where provided, are based on equity positions held by the ETF and exclude cash, currencies, and other holdings.
As of Oct 31, 2026
The Global X Genomics & Biotechnology ETF (GNOM) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.
The Global X Genomics & Biotechnology ETF (GNOM) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index.
The Index is designed to track the performance of companies positioned to benefit from further advances in the field of genomic science, including gene editing, genomic sequencing, genetic medicine and therapies, computational genomics, and genetic diagnostics. Companies are classified by their revenue exposure to these interconnected genomics activities: companies deriving at least 50% of revenue from Genomics Activities, Pre-Revenue companies with primary operations in Genomics Activities (but do not currently generate revenue), and Diversified companies with less than 50% revenue exposure also qualify as these diversified companies seek to make up a significant portion of current genomic revenues. The Index selects up to the top 50 such companies, ranked by their thematic relevance, with at least 5 diversified companies.
Highlights
As of Nov 9, 2026
As of Nov 9, 2026
| 10X GENOMICS INC-CLASS A |
| BKS3RS7 |
| $65.05 |
| 91,962 |
| $5,982,128 |
| 5.06% | GH | GUARDANT HEALTH INC | BFXC911 | $158.79 | 34,753 | $5,518,429 |
| 4.83% | ILMN | ILLUMINA INC | 2613990 | $220.78 | 23,851 | $5,265,824 |
| 4.40% | NTRA | NATERA INC | BYQRG48 | $320.39 | 14,979 | $4,799,122 |
| 3.61% | QGEN | QIAGEN N.V. | BVPJWL3 | $50.55 | 77,872 | $3,936,430 |
| 3.59% | VRTX | VERTEX PHARMACEUTICALS INC | 2931034 | $550.87 | 7,112 | $3,917,787 |
| 3.55% | TECH | BIO-TECHNE CORP | BSHZ3Q0 | $72.83 | 53,165 | $3,872,007 |
| 3.38% | 1548 HK | GENSCRIPT BIOTECH CORP | BD9Q2J2 | $3.99 | 922,818 | $3,685,718 |
The Premium/Discount chart demonstrates the difference between the daily market price of shares of the Fund and the Fund's net asset value (NAV). The vertical axis of the chart shows the premium or discount of the daily market price as a percentage of the NAV. The horizontal axis shows each trading day in the time period, and each data point in the chart represents the Premium/Discount on that day. The data presented in the chart and table above represent past performance and cannot be used to predict future results.
The primary explanation is that timing discrepancies can arise between the NAV and the trading price of the Fund. Since shares of the Fund trade on the open market, prices are affected by the constant flow of information received by investors, corporations and financial institutions. Depending on how this changing information affects investor sentiment, shares of the Fund may deviate slightly from the value of the Fund's underlying assets. The NAV of the Fund is only calculated once a day (normally at 4:00 p.m. eastern time). As a result, shareholders may pay more than NAV when they buy Fund shares and receive less than NAV when they sell those shares, because shares are purchased and sold at current market prices. However, due to the creation and redemption process that is unique to ETFs, market makers are able to minimize these deviations from NAV by taking advantage of arbitrage opportunities.
Close of Trading Times. Although both the NAV and the daily market price of the Fund are generally calculated based on prices at the closing time of the exchange (generally 4:00 p.m. eastern time), slight differences in this timing may cause discrepancies.
Time of Last Trade. Trading of Global X funds generally takes place during normal trading hours (9:30 a.m. to 4:00 p.m. eastern time). However, it is important to note that the last trade - from which the closing price is determined - may not occur at exactly 4:00 p.m. eastern time. Therefore, changing market sentiment during the time difference may cause the NAV to deviate from the closing price.
International Holdings. The premiums and discounts for funds with significant holdings in international markets may be less accurate due to the different closing times of various international markets. Because the Funds trade during U.S. market hours while the underlying securities may not, the time lapse between the markets can result in differences between the NAV and the trading price.
| Weight (%) |
|---|
United States | 85.43% |
|---|---|
Netherlands | 4.45% |
China | 3.65% |
Switzerland | 2.51% |
Germany | 2.24% |
Britain | 1.32% |
Singapore | 0.40% |
As of Nov 9, 2026
Source: AltaVista Research, LLC
